Lantern Pharma Stock Today

LTRN Stock  USD 3.21  0.10  3.22%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 19

 
High
 
Low
Low
Lantern Pharma is selling at 3.21 as of the 2nd of December 2024; that is 3.22 percent increase since the beginning of the trading day. The stock's open price was 3.11. Lantern Pharma has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Lantern Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of October 2024 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of June 2020
Category
Healthcare
Classification
Health Care
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. The company has 10.78 M outstanding shares of which 160.85 K shares are now shorted by private and institutional investors with about 4.74 trading days to cover. More on Lantern Pharma

Moving together with Lantern Stock

  0.77ME 23Andme Holding Upward RallyPairCorr
  0.61VALN Valneva SE ADRPairCorr

Moving against Lantern Stock

  0.65DRUG Bright Minds Biosciences TrendingPairCorr
  0.59SABSW SAB BiotherapeuticsPairCorr
  0.5VCYT VeracytePairCorr
  0.42VANI Vivani MedicalPairCorr
  0.38DMAC DiaMedica Therapeutics TrendingPairCorr
  0.38VERA Vera TherapeuticsPairCorr

Lantern Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentPanna Sharma
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Lantern Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lantern Pharma's financial leverage. It provides some insight into what part of Lantern Pharma's total assets is financed by creditors.
Liquidity
Lantern Pharma currently holds 234.47 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Lantern Pharma has a current ratio of 12.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lantern Pharma's use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

169,408
Lantern Pharma (LTRN) is traded on NASDAQ Exchange in USA. It is located in 1920 McKinney Avenue, Dallas, TX, United States, 75201 and employs 21 people. Lantern Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.62 M. Lantern Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.78 M outstanding shares of which 160.85 K shares are now shorted by private and institutional investors with about 4.74 trading days to cover. Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lantern Pharma Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Lantern Pharma is $34.62 Million. Lantern Pharma secures 14.74 % of its outstanding shares held by insiders and 24.1 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Lantern Ownership Details

Lantern Stock Institutional Holders

InstituionRecorded OnShares
Sigma Planning Corp2024-09-30
28.6 K
Horizon Asset Management Inc/ny2024-09-30
27.6 K
Ubs Group Ag2024-09-30
26.9 K
Bank Of New York Mellon Corp2024-09-30
26.5 K
State Street Corp2024-09-30
23.7 K
Susquehanna International Group, Llp2024-09-30
21.9 K
Tocqueville Asset Management L.p.2024-09-30
17 K
Northern Trust Corp2024-09-30
12.8 K
Honkamp Krueger Financial Services Inc2024-09-30
11.6 K
Vanguard Group Inc2024-09-30
363.7 K
Cm Management, Llc2024-09-30
185 K
View Lantern Pharma Diagnostics

Lantern Pharma Historical Income Statement

At this time, Lantern Pharma's Interest Income is very stable compared to the past year. View More Fundamentals

Lantern Stock Against Markets

Lantern Pharma Corporate Management

DVM MSCoFounder AdvisorProfile
Nicole LeberFinance AssociateProfile
MS BSHead OperationsProfile
Kishor BhatiaChief ConsultantProfile
Marc MDChief TherapeuticsProfile
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.78)
Return On Assets
(0.28)
Return On Equity
(0.45)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.